Company intelligence / Profile preview

Lavipharm

Ownership: Public · LAVI
Employees: ~299
Development stage: Commercial

Overview

Lavipharm is a leading developer and manufacturer of pharmaceutical products, particularly in transdermal drug delivery systems. It offers a wide range of products across several therapeutic areas.

Therapeutic areas: OncologyCardiovascularNeurology
Modalities: Transdermal Drug Delivery Systems (TDDS)small molecules
Industry: Biotech

Partnerships

L'OréalSynthélaboZentivaTikun Olam Europe

Financials

Market cap: $149.1M
Total revenue: $167.2B
Enterprise value: $14.4B

Beyond the preview

Go deeper on Lavipharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lavipharm.

Explore the full profile